^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Norepinephrine reuptake inhibitor

    Related drugs:
    3d
    Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b) (clinicaltrials.gov)
    P2/3, N=60, Active, not recruiting, Yale University | Enrolling by invitation --> Active, not recruiting
    Enrollment closed
    3d
    Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer (clinicaltrials.gov)
    P2, N=68, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2028
    Trial completion date
    3d
    Tapentadol induces progressive hepatic damage via disrupting Hippo-YAP and bile acid-FXR pathways: An integrated experimental and computational perspective. (PubMed, Tissue Cell)
    Our findings are further supported by in-silico analysis that showed strong binding affinity of TAP with key regulatory genes. Collectively, these findings suggest that TAP is a hepatotoxic agent and warrant further clinical trials to evaluate its effects in humans.
    Journal • IO biomarker
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • YAP1 (Yes associated protein 1) • HMOX1 (Heme Oxygenase 1) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • IL1B (Interleukin 1, beta) • LATS1 (Large Tumor Suppressor Kinase 1) • CAT (Catalase)
    6d
    Cistanche tubulosa phenylethanol glycoside liposome ameliorates oxaliplatin-induced peripheral neuropathy by promoting RNA N6-methyladenosine modification. (PubMed, Phytomedicine)
    CPhG alleviates oxaliplatin-induced peripheral neuropathy by dual mechanisms: reducing neuroinflammation via IL-6 suppression and promoting neuronal survival and regeneration through AKT activation and m6A-dependent epitranscriptomic regulation. Compared with duloxetine, CPhG demonstrated superior neuroprotective and anti-inflammatory effects, supporting its potential as a novel therapeutic agent for OIPN.
    Journal
    |
    IL6 (Interleukin 6) • FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • METTL14 (Methyltransferase 14) • METTL3 (Methyltransferase Like 3)
    |
    oxaliplatin
    8d
    Efficacy and safety of bupropion hydrochloride in the treatment of stroke: a multi-center, double-blind, and randomized controlled clinical trial (ChiCTR2500105746)
    P4, N=1054, Not yet recruiting, The First Affiliated Hospital of Chongqing Medical University; Venturepharm (hainan) Co., Ltd. | Initiation date: Aug 2025 --> Jan 2026
    Trial initiation date
    8d
    Rapid Antidepressant Effects of Low-Dose Intravenous Esketamine in Patients with Chronic Pain (ChiCTR2500111749)
    P4, N=450, Not yet recruiting, Shandong Provincial Hospital Affiliated to Shandong First Medical University; Shandong Provincial Hospital Affiliated to Shandong First Medical Univer
    New P4 trial
    11d
    The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia (clinicaltrials.gov)
    P=N/A, N=106, Recruiting, Beijing Tiantan Hospital | N=400 --> 106
    Enrollment change
    15d
    The Analgesic Efficacy and Safety of Venlafaxine in Patients With Herpes Zoster (clinicaltrials.gov)
    P=N/A, N=750, Recruiting, Beijing Tiantan Hospital
    New trial
    15d
    Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin (clinicaltrials.gov)
    P1, N=99, Completed, Children's Oncology Group | Active, not recruiting --> Completed | Trial completion date: Sep 2025 --> Dec 2025
    Trial completion • Trial completion date
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • busulfan • Azedra (iobenguane I 131)
    16d
    Desvenlafaxine for Preventive Treatment of Frequent Episodic Tension-type Headache (clinicaltrials.gov)
    P=N/A, N=432, Active, not recruiting, Tongji Hospital
    New trial
    16d
    RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia) (clinicaltrials.gov)
    P2, N=361, Active, not recruiting, Duke University | Trial completion date: Dec 2025 --> Apr 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date
    |
    modafinil
    16d
    Irritable Bowel Syndrome (IBS) Functional Magnetic Resonance Imaging (fMRI) With Desipramine (clinicaltrials.gov)
    P=N/A, N=18, Terminated, Washington University School of Medicine | N=70 --> 18 | Completed --> Terminated; Due to changes in trial personnel (co-investigator and research coordinator leaving the institution).
    Enrollment change • Trial termination